nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP3A4—prostate cancer	0.21	1	CbGaD
Palonosetron—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0554	0.113	CbGbCtD
Palonosetron—CYP1A2—Flutamide—prostate cancer	0.0461	0.0936	CbGbCtD
Palonosetron—CYP2D6—Bicalutamide—prostate cancer	0.0458	0.0931	CbGbCtD
Palonosetron—CYP2D6—Abiraterone—prostate cancer	0.0379	0.0772	CbGbCtD
Palonosetron—CYP1A2—Estrone—prostate cancer	0.0333	0.0677	CbGbCtD
Palonosetron—CYP3A4—Bicalutamide—prostate cancer	0.0291	0.0592	CbGbCtD
Palonosetron—CYP3A4—Estramustine—prostate cancer	0.0271	0.055	CbGbCtD
Palonosetron—CYP3A4—Abiraterone—prostate cancer	0.0241	0.0491	CbGbCtD
Palonosetron—CYP3A4—Flutamide—prostate cancer	0.0241	0.0491	CbGbCtD
Palonosetron—CYP1A2—Conjugated Estrogens—prostate cancer	0.0218	0.0443	CbGbCtD
Palonosetron—CYP1A2—Estradiol—prostate cancer	0.0191	0.0389	CbGbCtD
Palonosetron—CYP3A4—Cabazitaxel—prostate cancer	0.0178	0.0363	CbGbCtD
Palonosetron—CYP3A4—Estrone—prostate cancer	0.0174	0.0355	CbGbCtD
Palonosetron—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0155	0.0316	CbGbCtD
Palonosetron—CYP1A2—Etoposide—prostate cancer	0.0125	0.0254	CbGbCtD
Palonosetron—CYP3A4—Conjugated Estrogens—prostate cancer	0.0114	0.0232	CbGbCtD
Palonosetron—CYP3A4—Mitoxantrone—prostate cancer	0.0104	0.0211	CbGbCtD
Palonosetron—CYP3A4—Estradiol—prostate cancer	0.01	0.0204	CbGbCtD
Palonosetron—CYP3A4—Prednisone—prostate cancer	0.00861	0.0175	CbGbCtD
Palonosetron—CYP2D6—Doxorubicin—prostate cancer	0.00702	0.0143	CbGbCtD
Palonosetron—CYP3A4—Etoposide—prostate cancer	0.00654	0.0133	CbGbCtD
Palonosetron—CYP3A4—Docetaxel—prostate cancer	0.00599	0.0122	CbGbCtD
Palonosetron—Praziquantel—CYP3A43—prostate cancer	0.00486	0.654	CrCbGaD
Palonosetron—CYP3A4—Doxorubicin—prostate cancer	0.00446	0.00907	CbGbCtD
Palonosetron—Praziquantel—CYP3A5—prostate cancer	0.00122	0.164	CrCbGaD
Palonosetron—Praziquantel—CYP2C19—prostate cancer	0.000828	0.112	CrCbGaD
Palonosetron—Praziquantel—CYP3A4—prostate cancer	0.000527	0.0709	CrCbGaD
Palonosetron—Anxiety—Capecitabine—prostate cancer	7.85e-05	0.000386	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	7.83e-05	0.000385	CcSEcCtD
Palonosetron—Hepatobiliary disease—Epirubicin—prostate cancer	7.81e-05	0.000384	CcSEcCtD
Palonosetron—Anaphylactic shock—Docetaxel—prostate cancer	7.8e-05	0.000384	CcSEcCtD
Palonosetron—Discomfort—Capecitabine—prostate cancer	7.79e-05	0.000383	CcSEcCtD
Palonosetron—Epistaxis—Epirubicin—prostate cancer	7.78e-05	0.000383	CcSEcCtD
Palonosetron—Infection—Docetaxel—prostate cancer	7.75e-05	0.000381	CcSEcCtD
Palonosetron—Sinusitis—Epirubicin—prostate cancer	7.74e-05	0.000381	CcSEcCtD
Palonosetron—Hyperglycaemia—Doxorubicin—prostate cancer	7.73e-05	0.00038	CcSEcCtD
Palonosetron—Diarrhoea—Mitoxantrone—prostate cancer	7.72e-05	0.00038	CcSEcCtD
Palonosetron—Dry mouth—Capecitabine—prostate cancer	7.71e-05	0.000379	CcSEcCtD
Palonosetron—Vomiting—Estradiol—prostate cancer	7.7e-05	0.000379	CcSEcCtD
Palonosetron—Gastrointestinal pain—Etoposide—prostate cancer	7.68e-05	0.000378	CcSEcCtD
Palonosetron—Shock—Docetaxel—prostate cancer	7.68e-05	0.000378	CcSEcCtD
Palonosetron—Nervous system disorder—Docetaxel—prostate cancer	7.65e-05	0.000376	CcSEcCtD
Palonosetron—Rash—Estradiol—prostate cancer	7.64e-05	0.000376	CcSEcCtD
Palonosetron—Dermatitis—Estradiol—prostate cancer	7.63e-05	0.000375	CcSEcCtD
Palonosetron—Anaemia—Prednisone—prostate cancer	7.62e-05	0.000375	CcSEcCtD
Palonosetron—Tachycardia—Docetaxel—prostate cancer	7.62e-05	0.000375	CcSEcCtD
Palonosetron—Headache—Estradiol—prostate cancer	7.59e-05	0.000373	CcSEcCtD
Palonosetron—Skin disorder—Docetaxel—prostate cancer	7.58e-05	0.000373	CcSEcCtD
Palonosetron—Bradycardia—Epirubicin—prostate cancer	7.54e-05	0.000371	CcSEcCtD
Palonosetron—Infection—Capecitabine—prostate cancer	7.51e-05	0.000369	CcSEcCtD
Palonosetron—Anorexia—Docetaxel—prostate cancer	7.44e-05	0.000366	CcSEcCtD
Palonosetron—Shock—Capecitabine—prostate cancer	7.43e-05	0.000366	CcSEcCtD
Palonosetron—Abdominal pain—Etoposide—prostate cancer	7.42e-05	0.000365	CcSEcCtD
Palonosetron—Body temperature increased—Etoposide—prostate cancer	7.42e-05	0.000365	CcSEcCtD
Palonosetron—Nervous system disorder—Capecitabine—prostate cancer	7.41e-05	0.000364	CcSEcCtD
Palonosetron—Tachycardia—Capecitabine—prostate cancer	7.37e-05	0.000363	CcSEcCtD
Palonosetron—Skin disorder—Capecitabine—prostate cancer	7.34e-05	0.000361	CcSEcCtD
Palonosetron—Urinary tract disorder—Epirubicin—prostate cancer	7.32e-05	0.00036	CcSEcCtD
Palonosetron—Hypotension—Docetaxel—prostate cancer	7.29e-05	0.000359	CcSEcCtD
Palonosetron—Connective tissue disorder—Epirubicin—prostate cancer	7.28e-05	0.000358	CcSEcCtD
Palonosetron—Urethral disorder—Epirubicin—prostate cancer	7.26e-05	0.000357	CcSEcCtD
Palonosetron—Hepatobiliary disease—Doxorubicin—prostate cancer	7.22e-05	0.000355	CcSEcCtD
Palonosetron—Epistaxis—Doxorubicin—prostate cancer	7.2e-05	0.000354	CcSEcCtD
Palonosetron—Anorexia—Capecitabine—prostate cancer	7.2e-05	0.000354	CcSEcCtD
Palonosetron—Nausea—Estradiol—prostate cancer	7.2e-05	0.000354	CcSEcCtD
Palonosetron—Vomiting—Mitoxantrone—prostate cancer	7.18e-05	0.000353	CcSEcCtD
Palonosetron—Sinusitis—Doxorubicin—prostate cancer	7.16e-05	0.000352	CcSEcCtD
Palonosetron—Convulsion—Prednisone—prostate cancer	7.15e-05	0.000351	CcSEcCtD
Palonosetron—Hypertension—Prednisone—prostate cancer	7.12e-05	0.00035	CcSEcCtD
Palonosetron—Rash—Mitoxantrone—prostate cancer	7.12e-05	0.00035	CcSEcCtD
Palonosetron—Dermatitis—Mitoxantrone—prostate cancer	7.11e-05	0.00035	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.11e-05	0.00035	CcSEcCtD
Palonosetron—Headache—Mitoxantrone—prostate cancer	7.07e-05	0.000348	CcSEcCtD
Palonosetron—Hypotension—Capecitabine—prostate cancer	7.06e-05	0.000347	CcSEcCtD
Palonosetron—Insomnia—Docetaxel—prostate cancer	7.06e-05	0.000347	CcSEcCtD
Palonosetron—Myalgia—Prednisone—prostate cancer	7.02e-05	0.000345	CcSEcCtD
Palonosetron—Arthralgia—Prednisone—prostate cancer	7.02e-05	0.000345	CcSEcCtD
Palonosetron—Paraesthesia—Docetaxel—prostate cancer	7.01e-05	0.000345	CcSEcCtD
Palonosetron—Anxiety—Prednisone—prostate cancer	7e-05	0.000344	CcSEcCtD
Palonosetron—Bradycardia—Doxorubicin—prostate cancer	6.98e-05	0.000343	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	6.97e-05	0.000343	CcSEcCtD
Palonosetron—Dyspnoea—Docetaxel—prostate cancer	6.96e-05	0.000342	CcSEcCtD
Palonosetron—Somnolence—Docetaxel—prostate cancer	6.94e-05	0.000341	CcSEcCtD
Palonosetron—Discomfort—Prednisone—prostate cancer	6.94e-05	0.000341	CcSEcCtD
Palonosetron—Eye disorder—Epirubicin—prostate cancer	6.92e-05	0.000341	CcSEcCtD
Palonosetron—Hypersensitivity—Etoposide—prostate cancer	6.92e-05	0.00034	CcSEcCtD
Palonosetron—Tinnitus—Epirubicin—prostate cancer	6.91e-05	0.00034	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.88e-05	0.000339	CcSEcCtD
Palonosetron—Cardiac disorder—Epirubicin—prostate cancer	6.88e-05	0.000338	CcSEcCtD
Palonosetron—Dyspepsia—Docetaxel—prostate cancer	6.87e-05	0.000338	CcSEcCtD
Palonosetron—Insomnia—Capecitabine—prostate cancer	6.83e-05	0.000336	CcSEcCtD
Palonosetron—Paraesthesia—Capecitabine—prostate cancer	6.78e-05	0.000334	CcSEcCtD
Palonosetron—Decreased appetite—Docetaxel—prostate cancer	6.78e-05	0.000334	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—prostate cancer	6.77e-05	0.000333	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Docetaxel—prostate cancer	6.74e-05	0.000331	CcSEcCtD
Palonosetron—Asthenia—Etoposide—prostate cancer	6.74e-05	0.000331	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—prostate cancer	6.74e-05	0.000331	CcSEcCtD
Palonosetron—Dyspnoea—Capecitabine—prostate cancer	6.74e-05	0.000331	CcSEcCtD
Palonosetron—Anaphylactic shock—Prednisone—prostate cancer	6.73e-05	0.000331	CcSEcCtD
Palonosetron—Fatigue—Docetaxel—prostate cancer	6.73e-05	0.000331	CcSEcCtD
Palonosetron—Angiopathy—Epirubicin—prostate cancer	6.72e-05	0.000331	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—prostate cancer	6.72e-05	0.00033	CcSEcCtD
Palonosetron—Nausea—Mitoxantrone—prostate cancer	6.71e-05	0.00033	CcSEcCtD
Palonosetron—Immune system disorder—Epirubicin—prostate cancer	6.69e-05	0.000329	CcSEcCtD
Palonosetron—Infection—Prednisone—prostate cancer	6.69e-05	0.000329	CcSEcCtD
Palonosetron—Mediastinal disorder—Epirubicin—prostate cancer	6.68e-05	0.000328	CcSEcCtD
Palonosetron—Constipation—Docetaxel—prostate cancer	6.67e-05	0.000328	CcSEcCtD
Palonosetron—Pain—Docetaxel—prostate cancer	6.67e-05	0.000328	CcSEcCtD
Palonosetron—Dyspepsia—Capecitabine—prostate cancer	6.65e-05	0.000327	CcSEcCtD
Palonosetron—Chills—Epirubicin—prostate cancer	6.65e-05	0.000327	CcSEcCtD
Palonosetron—Pruritus—Etoposide—prostate cancer	6.64e-05	0.000327	CcSEcCtD
Palonosetron—Shock—Prednisone—prostate cancer	6.62e-05	0.000326	CcSEcCtD
Palonosetron—Arrhythmia—Epirubicin—prostate cancer	6.62e-05	0.000326	CcSEcCtD
Palonosetron—Nervous system disorder—Prednisone—prostate cancer	6.6e-05	0.000325	CcSEcCtD
Palonosetron—Tachycardia—Prednisone—prostate cancer	6.57e-05	0.000323	CcSEcCtD
Palonosetron—Decreased appetite—Capecitabine—prostate cancer	6.57e-05	0.000323	CcSEcCtD
Palonosetron—Alopecia—Epirubicin—prostate cancer	6.55e-05	0.000322	CcSEcCtD
Palonosetron—Skin disorder—Prednisone—prostate cancer	6.54e-05	0.000322	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Capecitabine—prostate cancer	6.52e-05	0.000321	CcSEcCtD
Palonosetron—Fatigue—Capecitabine—prostate cancer	6.51e-05	0.00032	CcSEcCtD
Palonosetron—Mental disorder—Epirubicin—prostate cancer	6.49e-05	0.000319	CcSEcCtD
Palonosetron—Pain—Capecitabine—prostate cancer	6.46e-05	0.000318	CcSEcCtD
Palonosetron—Constipation—Capecitabine—prostate cancer	6.46e-05	0.000318	CcSEcCtD
Palonosetron—Erythema—Epirubicin—prostate cancer	6.45e-05	0.000317	CcSEcCtD
Palonosetron—Malnutrition—Epirubicin—prostate cancer	6.45e-05	0.000317	CcSEcCtD
Palonosetron—Diarrhoea—Etoposide—prostate cancer	6.43e-05	0.000316	CcSEcCtD
Palonosetron—Anorexia—Prednisone—prostate cancer	6.42e-05	0.000316	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—prostate cancer	6.41e-05	0.000315	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—prostate cancer	6.39e-05	0.000314	CcSEcCtD
Palonosetron—Gastrointestinal pain—Docetaxel—prostate cancer	6.38e-05	0.000314	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—prostate cancer	6.36e-05	0.000313	CcSEcCtD
Palonosetron—Flatulence—Epirubicin—prostate cancer	6.36e-05	0.000313	CcSEcCtD
Palonosetron—Dysgeusia—Epirubicin—prostate cancer	6.32e-05	0.000311	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—prostate cancer	6.22e-05	0.000306	CcSEcCtD
Palonosetron—Dizziness—Etoposide—prostate cancer	6.21e-05	0.000305	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—prostate cancer	6.19e-05	0.000305	CcSEcCtD
Palonosetron—Gastrointestinal pain—Capecitabine—prostate cancer	6.18e-05	0.000304	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—prostate cancer	6.18e-05	0.000304	CcSEcCtD
Palonosetron—Abdominal pain—Docetaxel—prostate cancer	6.17e-05	0.000303	CcSEcCtD
Palonosetron—Body temperature increased—Docetaxel—prostate cancer	6.17e-05	0.000303	CcSEcCtD
Palonosetron—Chills—Doxorubicin—prostate cancer	6.15e-05	0.000303	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Prednisone—prostate cancer	6.13e-05	0.000302	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—prostate cancer	6.12e-05	0.000301	CcSEcCtD
Palonosetron—Insomnia—Prednisone—prostate cancer	6.09e-05	0.000299	CcSEcCtD
Palonosetron—Alopecia—Doxorubicin—prostate cancer	6.06e-05	0.000298	CcSEcCtD
Palonosetron—Paraesthesia—Prednisone—prostate cancer	6.04e-05	0.000297	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—prostate cancer	6.01e-05	0.000295	CcSEcCtD
Palonosetron—Abdominal pain—Capecitabine—prostate cancer	5.97e-05	0.000294	CcSEcCtD
Palonosetron—Body temperature increased—Capecitabine—prostate cancer	5.97e-05	0.000294	CcSEcCtD
Palonosetron—Vomiting—Etoposide—prostate cancer	5.97e-05	0.000294	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—prostate cancer	5.97e-05	0.000293	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—prostate cancer	5.97e-05	0.000293	CcSEcCtD
Palonosetron—Anaemia—Epirubicin—prostate cancer	5.96e-05	0.000293	CcSEcCtD
Palonosetron—Dyspepsia—Prednisone—prostate cancer	5.92e-05	0.000291	CcSEcCtD
Palonosetron—Rash—Etoposide—prostate cancer	5.92e-05	0.000291	CcSEcCtD
Palonosetron—Dermatitis—Etoposide—prostate cancer	5.92e-05	0.000291	CcSEcCtD
Palonosetron—Headache—Etoposide—prostate cancer	5.88e-05	0.000289	CcSEcCtD
Palonosetron—Flatulence—Doxorubicin—prostate cancer	5.88e-05	0.000289	CcSEcCtD
Palonosetron—Decreased appetite—Prednisone—prostate cancer	5.85e-05	0.000288	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—prostate cancer	5.84e-05	0.000287	CcSEcCtD
Palonosetron—Fatigue—Prednisone—prostate cancer	5.8e-05	0.000285	CcSEcCtD
Palonosetron—Constipation—Prednisone—prostate cancer	5.76e-05	0.000283	CcSEcCtD
Palonosetron—Hypersensitivity—Docetaxel—prostate cancer	5.75e-05	0.000283	CcSEcCtD
Palonosetron—Asthenia—Docetaxel—prostate cancer	5.6e-05	0.000275	CcSEcCtD
Palonosetron—Convulsion—Epirubicin—prostate cancer	5.59e-05	0.000275	CcSEcCtD
Palonosetron—Nausea—Etoposide—prostate cancer	5.58e-05	0.000274	CcSEcCtD
Palonosetron—Hypertension—Epirubicin—prostate cancer	5.57e-05	0.000274	CcSEcCtD
Palonosetron—Hypersensitivity—Capecitabine—prostate cancer	5.57e-05	0.000274	CcSEcCtD
Palonosetron—Pruritus—Docetaxel—prostate cancer	5.52e-05	0.000272	CcSEcCtD
Palonosetron—Anaemia—Doxorubicin—prostate cancer	5.52e-05	0.000271	CcSEcCtD
Palonosetron—Gastrointestinal pain—Prednisone—prostate cancer	5.5e-05	0.000271	CcSEcCtD
Palonosetron—Arthralgia—Epirubicin—prostate cancer	5.49e-05	0.00027	CcSEcCtD
Palonosetron—Myalgia—Epirubicin—prostate cancer	5.49e-05	0.00027	CcSEcCtD
Palonosetron—Anxiety—Epirubicin—prostate cancer	5.47e-05	0.000269	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.45e-05	0.000268	CcSEcCtD
Palonosetron—Discomfort—Epirubicin—prostate cancer	5.43e-05	0.000267	CcSEcCtD
Palonosetron—Asthenia—Capecitabine—prostate cancer	5.42e-05	0.000267	CcSEcCtD
Palonosetron—Dry mouth—Epirubicin—prostate cancer	5.37e-05	0.000264	CcSEcCtD
Palonosetron—Pruritus—Capecitabine—prostate cancer	5.35e-05	0.000263	CcSEcCtD
Palonosetron—Diarrhoea—Docetaxel—prostate cancer	5.34e-05	0.000263	CcSEcCtD
Palonosetron—Abdominal pain—Prednisone—prostate cancer	5.32e-05	0.000262	CcSEcCtD
Palonosetron—Body temperature increased—Prednisone—prostate cancer	5.32e-05	0.000262	CcSEcCtD
Palonosetron—Anaphylactic shock—Epirubicin—prostate cancer	5.26e-05	0.000259	CcSEcCtD
Palonosetron—Infection—Epirubicin—prostate cancer	5.23e-05	0.000257	CcSEcCtD
Palonosetron—Shock—Epirubicin—prostate cancer	5.18e-05	0.000255	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—prostate cancer	5.17e-05	0.000254	CcSEcCtD
Palonosetron—Diarrhoea—Capecitabine—prostate cancer	5.17e-05	0.000254	CcSEcCtD
Palonosetron—Nervous system disorder—Epirubicin—prostate cancer	5.16e-05	0.000254	CcSEcCtD
Palonosetron—Dizziness—Docetaxel—prostate cancer	5.16e-05	0.000254	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—prostate cancer	5.15e-05	0.000253	CcSEcCtD
Palonosetron—Tachycardia—Epirubicin—prostate cancer	5.14e-05	0.000253	CcSEcCtD
Palonosetron—Skin disorder—Epirubicin—prostate cancer	5.11e-05	0.000251	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—prostate cancer	5.08e-05	0.00025	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—prostate cancer	5.08e-05	0.00025	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—prostate cancer	5.06e-05	0.000249	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.05e-05	0.000248	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—prostate cancer	5.02e-05	0.000247	CcSEcCtD
Palonosetron—Anorexia—Epirubicin—prostate cancer	5.02e-05	0.000247	CcSEcCtD
Palonosetron—Dizziness—Capecitabine—prostate cancer	5e-05	0.000246	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—prostate cancer	4.97e-05	0.000244	CcSEcCtD
Palonosetron—Vomiting—Docetaxel—prostate cancer	4.96e-05	0.000244	CcSEcCtD
Palonosetron—Hypersensitivity—Prednisone—prostate cancer	4.96e-05	0.000244	CcSEcCtD
Palonosetron—Rash—Docetaxel—prostate cancer	4.92e-05	0.000242	CcSEcCtD
Palonosetron—Hypotension—Epirubicin—prostate cancer	4.92e-05	0.000242	CcSEcCtD
Palonosetron—Dermatitis—Docetaxel—prostate cancer	4.92e-05	0.000242	CcSEcCtD
Palonosetron—Headache—Docetaxel—prostate cancer	4.89e-05	0.00024	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—prostate cancer	4.87e-05	0.00024	CcSEcCtD
Palonosetron—Infection—Doxorubicin—prostate cancer	4.84e-05	0.000238	CcSEcCtD
Palonosetron—Asthenia—Prednisone—prostate cancer	4.83e-05	0.000237	CcSEcCtD
Palonosetron—Vomiting—Capecitabine—prostate cancer	4.8e-05	0.000236	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.8e-05	0.000236	CcSEcCtD
Palonosetron—Shock—Doxorubicin—prostate cancer	4.79e-05	0.000236	CcSEcCtD
Palonosetron—Nervous system disorder—Doxorubicin—prostate cancer	4.78e-05	0.000235	CcSEcCtD
Palonosetron—Rash—Capecitabine—prostate cancer	4.76e-05	0.000234	CcSEcCtD
Palonosetron—Pruritus—Prednisone—prostate cancer	4.76e-05	0.000234	CcSEcCtD
Palonosetron—Insomnia—Epirubicin—prostate cancer	4.76e-05	0.000234	CcSEcCtD
Palonosetron—Dermatitis—Capecitabine—prostate cancer	4.76e-05	0.000234	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—prostate cancer	4.75e-05	0.000234	CcSEcCtD
Palonosetron—Headache—Capecitabine—prostate cancer	4.73e-05	0.000233	CcSEcCtD
Palonosetron—Skin disorder—Doxorubicin—prostate cancer	4.73e-05	0.000233	CcSEcCtD
Palonosetron—Paraesthesia—Epirubicin—prostate cancer	4.73e-05	0.000232	CcSEcCtD
Palonosetron—Dyspnoea—Epirubicin—prostate cancer	4.69e-05	0.000231	CcSEcCtD
Palonosetron—Somnolence—Epirubicin—prostate cancer	4.68e-05	0.00023	CcSEcCtD
Palonosetron—Anorexia—Doxorubicin—prostate cancer	4.64e-05	0.000228	CcSEcCtD
Palonosetron—Nausea—Docetaxel—prostate cancer	4.64e-05	0.000228	CcSEcCtD
Palonosetron—Dyspepsia—Epirubicin—prostate cancer	4.63e-05	0.000228	CcSEcCtD
Palonosetron—Diarrhoea—Prednisone—prostate cancer	4.6e-05	0.000226	CcSEcCtD
Palonosetron—Decreased appetite—Epirubicin—prostate cancer	4.58e-05	0.000225	CcSEcCtD
Palonosetron—Hypotension—Doxorubicin—prostate cancer	4.55e-05	0.000224	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Epirubicin—prostate cancer	4.54e-05	0.000223	CcSEcCtD
Palonosetron—Fatigue—Epirubicin—prostate cancer	4.54e-05	0.000223	CcSEcCtD
Palonosetron—Constipation—Epirubicin—prostate cancer	4.5e-05	0.000221	CcSEcCtD
Palonosetron—Pain—Epirubicin—prostate cancer	4.5e-05	0.000221	CcSEcCtD
Palonosetron—Nausea—Capecitabine—prostate cancer	4.49e-05	0.000221	CcSEcCtD
Palonosetron—Dizziness—Prednisone—prostate cancer	4.45e-05	0.000219	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.44e-05	0.000218	CcSEcCtD
Palonosetron—Insomnia—Doxorubicin—prostate cancer	4.41e-05	0.000217	CcSEcCtD
Palonosetron—Paraesthesia—Doxorubicin—prostate cancer	4.37e-05	0.000215	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—prostate cancer	4.34e-05	0.000214	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—prostate cancer	4.33e-05	0.000213	CcSEcCtD
Palonosetron—Gastrointestinal pain—Epirubicin—prostate cancer	4.3e-05	0.000212	CcSEcCtD
Palonosetron—Dyspepsia—Doxorubicin—prostate cancer	4.29e-05	0.000211	CcSEcCtD
Palonosetron—Vomiting—Prednisone—prostate cancer	4.28e-05	0.00021	CcSEcCtD
Palonosetron—Rash—Prednisone—prostate cancer	4.24e-05	0.000209	CcSEcCtD
Palonosetron—Dermatitis—Prednisone—prostate cancer	4.24e-05	0.000209	CcSEcCtD
Palonosetron—Decreased appetite—Doxorubicin—prostate cancer	4.23e-05	0.000208	CcSEcCtD
Palonosetron—Headache—Prednisone—prostate cancer	4.22e-05	0.000207	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.2e-05	0.000207	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—prostate cancer	4.2e-05	0.000207	CcSEcCtD
Palonosetron—Pain—Doxorubicin—prostate cancer	4.16e-05	0.000205	CcSEcCtD
Palonosetron—Constipation—Doxorubicin—prostate cancer	4.16e-05	0.000205	CcSEcCtD
Palonosetron—Abdominal pain—Epirubicin—prostate cancer	4.16e-05	0.000205	CcSEcCtD
Palonosetron—Body temperature increased—Epirubicin—prostate cancer	4.16e-05	0.000205	CcSEcCtD
Palonosetron—Nausea—Prednisone—prostate cancer	4e-05	0.000197	CcSEcCtD
Palonosetron—Gastrointestinal pain—Doxorubicin—prostate cancer	3.98e-05	0.000196	CcSEcCtD
Palonosetron—Hypersensitivity—Epirubicin—prostate cancer	3.88e-05	0.000191	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—prostate cancer	3.85e-05	0.000189	CcSEcCtD
Palonosetron—Body temperature increased—Doxorubicin—prostate cancer	3.85e-05	0.000189	CcSEcCtD
Palonosetron—Asthenia—Epirubicin—prostate cancer	3.78e-05	0.000186	CcSEcCtD
Palonosetron—Pruritus—Epirubicin—prostate cancer	3.72e-05	0.000183	CcSEcCtD
Palonosetron—Diarrhoea—Epirubicin—prostate cancer	3.6e-05	0.000177	CcSEcCtD
Palonosetron—Hypersensitivity—Doxorubicin—prostate cancer	3.59e-05	0.000176	CcSEcCtD
Palonosetron—Asthenia—Doxorubicin—prostate cancer	3.49e-05	0.000172	CcSEcCtD
Palonosetron—Dizziness—Epirubicin—prostate cancer	3.48e-05	0.000171	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—prostate cancer	3.45e-05	0.000169	CcSEcCtD
Palonosetron—Vomiting—Epirubicin—prostate cancer	3.35e-05	0.000165	CcSEcCtD
Palonosetron—Diarrhoea—Doxorubicin—prostate cancer	3.33e-05	0.000164	CcSEcCtD
Palonosetron—Rash—Epirubicin—prostate cancer	3.32e-05	0.000163	CcSEcCtD
Palonosetron—Dermatitis—Epirubicin—prostate cancer	3.32e-05	0.000163	CcSEcCtD
Palonosetron—Headache—Epirubicin—prostate cancer	3.3e-05	0.000162	CcSEcCtD
Palonosetron—Dizziness—Doxorubicin—prostate cancer	3.22e-05	0.000158	CcSEcCtD
Palonosetron—Nausea—Epirubicin—prostate cancer	3.13e-05	0.000154	CcSEcCtD
Palonosetron—Vomiting—Doxorubicin—prostate cancer	3.1e-05	0.000152	CcSEcCtD
Palonosetron—Rash—Doxorubicin—prostate cancer	3.07e-05	0.000151	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—prostate cancer	3.07e-05	0.000151	CcSEcCtD
Palonosetron—Headache—Doxorubicin—prostate cancer	3.05e-05	0.00015	CcSEcCtD
Palonosetron—Nausea—Doxorubicin—prostate cancer	2.89e-05	0.000142	CcSEcCtD
Palonosetron—CYP3A4—Metabolism—NAGLU—prostate cancer	1.39e-05	0.000159	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—RFK—prostate cancer	1.39e-05	0.000159	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AOX1—prostate cancer	1.39e-05	0.000159	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTM3—prostate cancer	1.39e-05	0.000159	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PGAM2—prostate cancer	1.39e-05	0.000159	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—LDHB—prostate cancer	1.37e-05	0.000157	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TNFRSF21—prostate cancer	1.36e-05	0.000156	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP3A5—prostate cancer	1.34e-05	0.000154	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP7B1—prostate cancer	1.32e-05	0.000152	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MTAP—prostate cancer	1.32e-05	0.000152	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.31e-05	0.000151	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AMACR—prostate cancer	1.31e-05	0.000151	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.31e-05	0.000151	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NAT1—prostate cancer	1.31e-05	0.000151	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—DEGS1—prostate cancer	1.31e-05	0.000151	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TCN2—prostate cancer	1.3e-05	0.000149	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PDHA1—prostate cancer	1.3e-05	0.000149	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA3—prostate cancer	1.3e-05	0.000149	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—UCP3—prostate cancer	1.3e-05	0.000149	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	1.29e-05	0.000149	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SULT1E1—prostate cancer	1.29e-05	0.000148	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SRD5A1—prostate cancer	1.29e-05	0.000148	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.25e-05	0.000144	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	1.25e-05	0.000144	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HSD3B1—prostate cancer	1.24e-05	0.000142	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC22A3—prostate cancer	1.24e-05	0.000142	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	1.23e-05	0.000142	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ACSL4—prostate cancer	1.23e-05	0.000141	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HSD17B3—prostate cancer	1.23e-05	0.000141	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	1.22e-05	0.00014	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TBXAS1—prostate cancer	1.18e-05	0.000136	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA4—prostate cancer	1.18e-05	0.000136	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ARG2—prostate cancer	1.18e-05	0.000136	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PHGDH—prostate cancer	1.18e-05	0.000136	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—UMPS—prostate cancer	1.18e-05	0.000136	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	1.17e-05	0.000135	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—LDHB—prostate cancer	1.16e-05	0.000133	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA2—prostate cancer	1.15e-05	0.000133	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SULT1A1—prostate cancer	1.14e-05	0.000131	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ABCG5—prostate cancer	1.14e-05	0.000131	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP3A5—prostate cancer	1.14e-05	0.000131	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.12e-05	0.000128	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HPGD—prostate cancer	1.12e-05	0.000128	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA1—prostate cancer	1.11e-05	0.000128	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTO1—prostate cancer	1.1e-05	0.000127	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HSD3B2—prostate cancer	1.1e-05	0.000127	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NAT2—prostate cancer	1.1e-05	0.000127	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—UCP3—prostate cancer	1.1e-05	0.000126	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PDHA1—prostate cancer	1.1e-05	0.000126	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TCN2—prostate cancer	1.1e-05	0.000126	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA3—prostate cancer	1.1e-05	0.000126	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PLCB2—prostate cancer	1.06e-05	0.000121	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP2C18—prostate cancer	1.06e-05	0.000121	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—LRP2—prostate cancer	1.06e-05	0.000121	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.05e-05	0.000121	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HSD3B1—prostate cancer	1.05e-05	0.00012	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC22A3—prostate cancer	1.05e-05	0.00012	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—P4HB—prostate cancer	1.04e-05	0.000119	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MTAP—prostate cancer	1.02e-05	0.000117	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.02e-05	0.000117	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.02e-05	0.000117	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC22A1—prostate cancer	1.01e-05	0.000116	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TBXAS1—prostate cancer	1e-05	0.000115	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA4—prostate cancer	1e-05	0.000115	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SULT1E1—prostate cancer	9.96e-06	0.000114	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SRD5A1—prostate cancer	9.96e-06	0.000114	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SULT2A1—prostate cancer	9.82e-06	0.000113	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	9.81e-06	0.000113	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA2—prostate cancer	9.78e-06	0.000112	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ABCG5—prostate cancer	9.66e-06	0.000111	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SULT1A1—prostate cancer	9.66e-06	0.000111	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—MED12—prostate cancer	9.66e-06	0.000111	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GNG5—prostate cancer	9.58e-06	0.00011	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ACSL4—prostate cancer	9.5e-06	0.000109	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HSD17B3—prostate cancer	9.5e-06	0.000109	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA1—prostate cancer	9.44e-06	0.000108	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NAT2—prostate cancer	9.33e-06	0.000107	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HSD3B2—prostate cancer	9.33e-06	0.000107	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTO1—prostate cancer	9.33e-06	0.000107	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NCOA3—prostate cancer	9.23e-06	0.000106	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—UMPS—prostate cancer	9.11e-06	0.000105	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PHGDH—prostate cancer	9.11e-06	0.000105	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ARG2—prostate cancer	9.11e-06	0.000105	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	8.97e-06	0.000103	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—LRP2—prostate cancer	8.95e-06	0.000103	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PLCB2—prostate cancer	8.95e-06	0.000103	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP2C18—prostate cancer	8.95e-06	0.000103	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—LDHB—prostate cancer	8.93e-06	0.000103	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HPGDS—prostate cancer	8.81e-06	0.000101	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—P4HB—prostate cancer	8.77e-06	0.000101	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP3A5—prostate cancer	8.77e-06	0.000101	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP2C19—prostate cancer	8.75e-06	0.000101	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ACHE—prostate cancer	8.54e-06	9.81e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTT1—prostate cancer	8.54e-06	9.81e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC22A1—prostate cancer	8.53e-06	9.81e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—UCP3—prostate cancer	8.47e-06	9.73e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TCN2—prostate cancer	8.47e-06	9.73e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA3—prostate cancer	8.47e-06	9.73e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PDHA1—prostate cancer	8.47e-06	9.73e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP2A6—prostate cancer	8.44e-06	9.7e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.44e-06	9.69e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SULT2A1—prostate cancer	8.32e-06	9.56e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—AKR1C3—prostate cancer	8.21e-06	9.44e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MED12—prostate cancer	8.18e-06	9.4e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PRKACB—prostate cancer	8.17e-06	9.39e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GNG5—prostate cancer	8.12e-06	9.33e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP17A1—prostate cancer	8.08e-06	9.29e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HSD3B1—prostate cancer	8.08e-06	9.28e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC22A3—prostate cancer	8.08e-06	9.28e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NCOA3—prostate cancer	7.82e-06	8.98e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TBXAS1—prostate cancer	7.75e-06	8.9e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA4—prostate cancer	7.75e-06	8.9e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NCOA2—prostate cancer	7.7e-06	8.85e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.68e-06	8.83e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA2—prostate cancer	7.55e-06	8.67e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HPGDS—prostate cancer	7.46e-06	8.57e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SULT1A1—prostate cancer	7.46e-06	8.57e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ABCG5—prostate cancer	7.46e-06	8.57e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP2C19—prostate cancer	7.41e-06	8.52e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—SLC5A5—prostate cancer	7.35e-06	8.44e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA1—prostate cancer	7.28e-06	8.37e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTT1—prostate cancer	7.24e-06	8.31e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ACHE—prostate cancer	7.24e-06	8.31e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTO1—prostate cancer	7.2e-06	8.27e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HSD3B2—prostate cancer	7.2e-06	8.27e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NAT2—prostate cancer	7.2e-06	8.27e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP2E1—prostate cancer	7.18e-06	8.25e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP2A6—prostate cancer	7.15e-06	8.22e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	7.12e-06	8.19e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NQO1—prostate cancer	7.1e-06	8.15e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TH—prostate cancer	7e-06	8.04e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—AKR1C3—prostate cancer	6.96e-06	7.99e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP3A4—prostate cancer	6.92e-06	7.95e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PRKACB—prostate cancer	6.92e-06	7.95e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PLCB2—prostate cancer	6.9e-06	7.93e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—LRP2—prostate cancer	6.9e-06	7.93e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.9e-06	7.93e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP17A1—prostate cancer	6.85e-06	7.87e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1B1—prostate cancer	6.81e-06	7.82e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—P4HB—prostate cancer	6.77e-06	7.78e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.76e-06	7.76e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GGT1—prostate cancer	6.59e-06	7.57e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC22A1—prostate cancer	6.59e-06	7.57e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NCOA2—prostate cancer	6.53e-06	7.5e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NCOA1—prostate cancer	6.49e-06	7.46e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SULT2A1—prostate cancer	6.42e-06	7.37e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP19A1—prostate cancer	6.4e-06	7.35e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MED12—prostate cancer	6.32e-06	7.26e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GNG5—prostate cancer	6.27e-06	7.2e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—SLC5A5—prostate cancer	6.23e-06	7.15e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—RXRA—prostate cancer	6.18e-06	7.09e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP2E1—prostate cancer	6.08e-06	6.99e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NCOA3—prostate cancer	6.04e-06	6.93e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NQO1—prostate cancer	6.01e-06	6.91e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—COMT—prostate cancer	5.95e-06	6.83e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TH—prostate cancer	5.93e-06	6.81e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTP1—prostate cancer	5.92e-06	6.8e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.89e-06	6.76e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP3A4—prostate cancer	5.86e-06	6.74e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.83e-06	6.7e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ITPR1—prostate cancer	5.83e-06	6.69e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP1B1—prostate cancer	5.77e-06	6.62e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HPGDS—prostate cancer	5.76e-06	6.61e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.72e-06	6.57e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ACHE—prostate cancer	5.58e-06	6.42e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTT1—prostate cancer	5.58e-06	6.42e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GGT1—prostate cancer	5.58e-06	6.41e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP2A6—prostate cancer	5.52e-06	6.34e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TYMS—prostate cancer	5.5e-06	6.32e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NCOA1—prostate cancer	5.5e-06	6.32e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTM1—prostate cancer	5.44e-06	6.25e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP19A1—prostate cancer	5.42e-06	6.23e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.37e-06	6.17e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PRKACB—prostate cancer	5.34e-06	6.14e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—LPL—prostate cancer	5.34e-06	6.14e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.29e-06	6.07e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—RXRA—prostate cancer	5.23e-06	6.01e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1A1—prostate cancer	5.16e-06	5.93e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ERCC2—prostate cancer	5.12e-06	5.88e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.09e-06	5.85e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—COMT—prostate cancer	5.04e-06	5.79e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NCOA2—prostate cancer	5.04e-06	5.79e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTP1—prostate cancer	5.02e-06	5.76e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ITPR1—prostate cancer	4.94e-06	5.67e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.85e-06	5.57e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—MTHFR—prostate cancer	4.81e-06	5.52e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.81e-06	5.52e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PPARA—prostate cancer	4.72e-06	5.42e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.69e-06	5.39e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TYMS—prostate cancer	4.66e-06	5.36e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NQO1—prostate cancer	4.64e-06	5.33e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTM1—prostate cancer	4.61e-06	5.3e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TH—prostate cancer	4.57e-06	5.25e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—LPL—prostate cancer	4.52e-06	5.2e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.45e-06	5.11e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CAV1—prostate cancer	4.43e-06	5.1e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP1A1—prostate cancer	4.37e-06	5.02e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ERCC2—prostate cancer	4.33e-06	4.98e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GGT1—prostate cancer	4.31e-06	4.95e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NCOA1—prostate cancer	4.24e-06	4.88e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.18e-06	4.81e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MTHFR—prostate cancer	4.07e-06	4.68e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CG—prostate cancer	4.04e-06	4.64e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—RXRA—prostate cancer	4.04e-06	4.64e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PPARA—prostate cancer	4e-06	4.59e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—COMT—prostate cancer	3.89e-06	4.47e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTP1—prostate cancer	3.87e-06	4.45e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—INS—prostate cancer	3.82e-06	4.39e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ITPR1—prostate cancer	3.81e-06	4.38e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CAV1—prostate cancer	3.76e-06	4.32e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CREBBP—prostate cancer	3.75e-06	4.3e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TYMS—prostate cancer	3.6e-06	4.13e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.59e-06	4.12e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTM1—prostate cancer	3.56e-06	4.09e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CD—prostate cancer	3.55e-06	4.08e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—LPL—prostate cancer	3.49e-06	4.01e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CG—prostate cancer	3.42e-06	3.93e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.37e-06	3.87e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NOS3—prostate cancer	3.35e-06	3.85e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ERCC2—prostate cancer	3.34e-06	3.84e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—INS—prostate cancer	3.24e-06	3.72e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CREBBP—prostate cancer	3.17e-06	3.65e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MTHFR—prostate cancer	3.14e-06	3.61e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CB—prostate cancer	3.1e-06	3.56e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PPARA—prostate cancer	3.08e-06	3.54e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTGS2—prostate cancer	3.07e-06	3.52e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.01e-06	3.46e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CAV1—prostate cancer	2.9e-06	3.33e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NOS3—prostate cancer	2.84e-06	3.26e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PTEN—prostate cancer	2.67e-06	3.07e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.64e-06	3.03e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CB—prostate cancer	2.62e-06	3.01e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTGS2—prostate cancer	2.6e-06	2.99e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—EP300—prostate cancer	2.55e-06	2.93e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—INS—prostate cancer	2.5e-06	2.87e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CREBBP—prostate cancer	2.45e-06	2.81e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.32e-06	2.67e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PTEN—prostate cancer	2.27e-06	2.6e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NOS3—prostate cancer	2.19e-06	2.52e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—EP300—prostate cancer	2.16e-06	2.48e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.02e-06	2.33e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTGS2—prostate cancer	2.01e-06	2.3e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.89e-06	2.17e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PTEN—prostate cancer	1.75e-06	2.01e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—EP300—prostate cancer	1.67e-06	1.92e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.6e-06	1.84e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—AKT1—prostate cancer	1.54e-06	1.77e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—AKT1—prostate cancer	1.31e-06	1.5e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.23e-06	1.42e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AKT1—prostate cancer	1.01e-06	1.16e-05	CbGpPWpGaD
